South San Francisco, CA, United States of America

Wouter Korver

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 8.3

ph-index = 6

Forward Citations = 82(Granted Patents)


Location History:

  • Mountain View, CA (US) (2017 - 2021)
  • South San Francisco, CA (US) (2013 - 2022)

Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Wouter Korver: Innovator in Anti-CD38 Therapeutics

Introduction

Wouter Korver is a prominent inventor based in South San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents targeting CD38, a protein implicated in multiple myeloma.

Latest Patents

Korver holds 13 patents that showcase his innovative work. His latest patents include anti-CD38 binding domains, which provide a composition comprising these domains, nucleic acids encoding them, and methods for using them in treating multiple myeloma. Another notable patent involves isolated antibodies that bind to human CD38 and cynomolgus CD38, along with pharmaceutical compositions and methods for therapeutic and diagnostic applications.

Career Highlights

Throughout his career, Wouter Korver has worked with leading pharmaceutical companies, including Takeda Pharmaceutical Company Limited and Teva Pharmaceuticals Australia Pty Ltd. His experience in these organizations has allowed him to advance his research and contribute to the development of novel therapies.

Collaborations

Some of his notable coworkers include Kathleen Ann Elias and Gregory M Landes. Their collaborative efforts have further enhanced the impact of Korver's inventions in the field.

Conclusion

Wouter Korver's innovative work in anti-CD38 therapeutics has positioned him as a key figure in biotechnology. His patents and collaborations reflect his commitment to advancing medical science and improving treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…